Literature DB >> 11530801

Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction.

H J Deeg1.   

Abstract

Graft-versus-host disease (GVHD) is the major complication after allogeneic hemopoietic stem cell transplantation. GVHD is destructive by itself and sets the stage for other sequelae, in particular, overwhelming infections. Recent investigations have improved our understanding of the underlying pathophysiology of GVHD. There are now compelling data on the role of host tissue destruction as the initial insult, extensive interactions of cellular donor and host components, a complex network of cytokines, adhesion molecules, and other components in the development of GVHD. The improved understanding of interactions among various signals is likely to allow for the development of new prophylactic strategies. A review of the data shows, however, that results are very dependent upon the models used. It is difficult or impossible to separate completely the discussion of cytokines that affect hemopoietic cells from discussion of cytokines that exert effects on immune cells. Furthermore, secondary effects on immune cells via hemopoietic cells complicate the picture. Application of the principles of cytokine signaling to the clinical setting may necessitate new trial design structures that take into consideration donor and host characteristics as well as the kinetics of GVHD development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11530801     DOI: 10.1007/BF02982546

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  70 in total

1.  Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease.

Authors:  P Hervé; M Flesch; P Tiberghien; J Wijdenes; E Racadot; P Bordigoni; E Plouvier; J L Stephan; H Bourdeau; E Holler
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

2.  IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells.

Authors:  H P Brok; J M Vossen; P J Heidt
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

3.  Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.

Authors:  O I Krijanovski; G R Hill; K R Cooke; T Teshima; J M Crawford; Y S Brinson; J L Ferrara
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

4.  Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease.

Authors:  K Miwa; H Hashimoto; T Yatomi; N Nakamura; S Nagata; T Suda
Journal:  Int Immunol       Date:  1999-06       Impact factor: 4.823

5.  Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.

Authors:  N Tsukada; T Kobata; Y Aizawa; H Yagita; K Okumura
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.

Authors:  T Iwasaki; T Hamano; K Saheki; T Kuroiwa; Y Kataoka; Y Takemoto; A Ogata; A Sugihara; N Terada; J Fujimoto; E Kakishita
Journal:  Cell Immunol       Date:  1999-10-10       Impact factor: 4.868

7.  Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease.

Authors:  M R van den Brink; E Moore; K J Horndasch; J M Crawford; G F Murphy; S J Burakoff
Journal:  Transplantation       Date:  2000-07-15       Impact factor: 4.939

8.  Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.

Authors:  V Rocha; J E Wagner; K A Sobocinski; J P Klein; M J Zhang; M M Horowitz; E Gluckman
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

9.  Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.

Authors:  A Shustov; P Nguyen; F Finkelman; K B Elkon; C S Via
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

10.  Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease.

Authors:  L M Liem; W E Fibbe; H C van Houwelingen; E Goulmy
Journal:  Transplantation       Date:  1999-01-15       Impact factor: 4.939

View more
  8 in total

1.  Cytokines and hematology.

Authors:  S Kasakura
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

Review 2.  Application of natural killer T-cells to posttransplantation immunotherapy.

Authors:  Shin-ichiro Fujii
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study.

Authors:  K Scott Baker; Kirsten K Ness; Julia Steinberger; Andrea Carter; Liton Francisco; Linda J Burns; Charles Sklar; Stephen Forman; Daniel Weisdorf; James G Gurney; Smita Bhatia
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 4.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

5.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

6.  Selective depletion of the allo-antigen specific T cells by Fas/FasL pathway by cytokine IFN-gamma and IL-2.

Authors:  Juan Xiao; Ping Zou; Zhongwen Liu; Lingbo Liu; Zhongbo Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

Review 7.  New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.

Authors:  H Joachim Deeg
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

8.  Chemotherapy-induced pulmonary complications in cancer: Significance of clinicoradiological correlation.

Authors:  Ekta Dhamija; Pankaj Meena; Vidyasagar Ramalingam; Ranjeet Sahoo; Sameer Rastogi; Sanjay Thulkar
Journal:  Indian J Radiol Imaging       Date:  2020-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.